Related Experiment Videos
Insights
Co-trimazine tablets demonstrate comparable effectiveness to co-trimoxazole for pediatric urinary tract infections, with a low incidence of side effects. A new sucrose-free suspension also showed high acceptability in young children.
Area of Science:
- Pediatric infectious diseases
- Pharmacology
- Antimicrobial therapy
Background:
- Urinary tract infections (UTIs) are common in children.
- Antibiotic resistance necessitates evaluating alternative treatments.
- Co-trimoxazole is a standard treatment, but dose optimization is key.
Purpose of the Study:
- To compare the efficacy and safety of co-trimazine with co-trimoxazole in treating pediatric UTIs.
- To assess the acceptability and tolerability of a new sucrose-free co-trimazine suspension in young children.
Main Methods:
- A comparative study involving 52 children with UTIs treated with co-trimazine tablets.
- Evaluation of side effects, including gastro-intestinal intolerance and allergic reactions.
- A separate trial assessing the acceptability of a sucrose-free co-trimazine suspension in 44 children.
Main Results:
- Co-trimazine was found to be at least as effective as co-trimoxazole.
- The frequency of adverse events such as gastro-intestinal issues and allergic reactions was low.
- The sucrose-free co-trimazine suspension exhibited high acceptability, with only one child refusing medication.
Conclusions:
- Co-trimazine offers a viable alternative to co-trimoxazole for pediatric UTIs.
- The new sucrose-free suspension is well-tolerated and acceptable for younger children.
- Further research may explore optimal dosing strategies for co-trimazine in pediatric populations.
Abstract:
A study of co-trimazine tablets in 52 cases of urinary tract infection in children has shown that co-trimazine is at least as effective as co-trimoxazole, in which both the sulphonamide and the trimethoprim dose is higher than with co-trimazine. The frequency of side-effects (gastro-intestinal intolerance and allergic manifestations) was low. A sucrose-free suspension of cotrimazine for use in younger children was tested and found to have very good properties, as judged by a high acceptability rate among the young patients. Only one of 44 children refused to take the medicine during the prescribed fourteen days of therapy.